Scarica l'app Stockscreener
5.22
0.76%
-0.04
Dopo l'orario di chiusura:
5.11
-0.11
-2.11%
Precedente Chiudi:
$5.26
Aprire:
$5.26
Volume 24 ore:
175.28K
Relative Volume:
0.70
Capitalizzazione di mercato:
$243.19M
Reddito:
-
Utile/perdita netta:
$-293.42M
Rapporto P/E:
-0.1948
EPS:
-26.8031
Flusso di cassa netto:
$-13.51M
1 W Prestazione:
+19.72%
1M Prestazione:
-20.61%
6M Prestazione:
+38.10%
1 anno Prestazione:
+257.53%
Intervallo 1D:
$5.05
$5.495
Intervallo di 1 settimana:
$4.32
$5.61
Portata 52W:
$1.35
$12.46
Minerva Neurosciences Inc Stock (NERV) Company Profile
Nome
Minerva Neurosciences Inc
Settore
Industria
Telefono
617-600-7373
Indirizzo
1500 DISTRICT AVENUE, BURLINGTON, MA
Compare NERV vs VRTX, REGN, ARGX, ALNY, RVMD
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
NERV
Minerva Neurosciences Inc
|
5.22 | 245.06M | 0 | -293.42M | -13.51M | -26.80 |
VRTX
Vertex Pharmaceuticals Inc
|
435.93 | 110.28B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
634.62 | 66.98B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
808.43 | 50.15B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
295.50 | 39.71B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
154.89 | 32.22B | 742.00K | -1.37B | -1.07B | -7.0731 |
Minerva Neurosciences Inc Stock (NERV) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2026-04-15 | Iniziato | Citizens | Mkt Outperform |
| 2020-06-08 | Reiterato | H.C. Wainwright | Buy |
| 2020-05-14 | Iniziato | BTIG Research | Buy |
| 2019-10-02 | Reiterato | Chardan Capital Markets | Buy |
| 2019-09-25 | Iniziato | Chardan Capital Markets | Buy |
| 2019-09-18 | Iniziato | William Blair | Outperform |
| 2019-05-31 | Iniziato | H.C. Wainwright | Buy |
| 2017-09-01 | Iniziato | Citigroup | Buy |
| 2017-03-06 | Ripresa | Jefferies | Buy |
| 2016-05-12 | Ripresa | Jefferies | Buy |
Mostra tutto
Minerva Neurosciences Inc Borsa (NERV) Ultime notizie
Minerva Neurosciences Inc (NERV) Q1 2026 Earnings: Wider Loss Highlights Ongoing Pre-Revenue Development StageDownward Estimate Revision - Newser
Minerva Neurosciences Q1 2026 Earnings: EPS Misses Estimates as Clinical-Stage Biotech Faces Challenges - Newser
All you need to know about Minerva Neurosciences (NERV) rating upgrade to buy - MSN
Minerva Neurosciences Q1 2026 Earnings: EPS Misses Street Estimates, Stock Gains on Pipeline OptimismPost-Earnings Drift - Newser
NERV Should I Buy - Intellectia AI
All You Need to Know About Minerva Neurosciences (NERV) Rating Upgrade to Buy - Yahoo Finance
Minerva Neurosciences (NERV) Loses 37.5% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner - Yahoo Finance
Minerva Neurosciences to Participate in the 2026 Jefferies Global Healthcare Conference - Investing News Network
Minerva CEO to join Jefferies 2026 healthcare fireside chat June 4 - Stock Titan
Minerva Neurosciences (NERV) Slides -5.22% as Selling Pressure Mounts 2026-05-15Popular Market Picks - Newser
Janus Henderson (NERV) reports 4.3M shares, 9.9% stake disclosed - Stock Titan
Balyasny group (NASDAQ: NERV) discloses a 9.99% stake of 4.32M shares - Stock Titan
TradingKey - TradingKey
Minerva Neurosciences (NERV) Slips -0.90%, Testing $5.22 Support 2026-05-14Social Momentum Signals - newser.com
H.C. Wainwright Maintains Minerva Neurosciences(NERV.US) With Hold Rating, Raises Target Price to $7 - Moomoo
8-K: Minerva Neurosciences Provides First Quarter 2026 Financial Results and Business Updatesmoomoo - Moomoo
Minerva Neurosciences, Inc. 1Q 2026: Revenue $0 Net loss $(125.4M), EPS $(2.86) — 10-Q Summary - TradingView
Minerva Neurosciences, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026 - marketscreener.com
Minerva Neurosciences (NERV) posts large Q1 2026 non-cash loss but keeps cash runway - Stock Titan
Minerva Neurosciences Posts 1Q $109.4M Non-Cash Expense For Change in Fair Value of Warrant Liability, Losses Recognized Upon Exercise of Warrants - Moomoo
Phase 3 roluperidone trial and larger Q1 loss at Minerva (NERV) - Stock Titan
Minerva Neurosciences: Q1 Earnings Snapshot - marketscreener.com
No approved drug targets these schizophrenia symptoms; Phase 3 starts - Stock Titan
Press Release: Minerva Neurosciences Provides First Quarter 2026 Financial Results and Business Updates - Moomoo
Minerva Neurosciences starts Phase 3 trial for roluperidone to treat negative schizophrenia symptoms - Pluang
Minerva Neurosciences, Inc (NASDAQ:NERV) Short Interest Update - MarketBeat
Minerva launched with new outperform at Citizens on schizophrenia candidate - MSN
Minerva Neurosciences (NERV) price target increased by 31.03% to 9.69 - MSN
Minerva Neurosciences | 8-K: Current report - Moomoo
NERV SEC FilingsMinerva Neurosci 10-K, 10-Q, 8-K Forms - Stock Titan
[ARS] Minerva Neurosciences, Inc. SEC Filing - Stock Titan
Officer liability and pay votes at Minerva Neurosciences (NASDAQ: NERV) 2026 meeting - Stock Titan
NERV (Minerva Neurosciences Inc) posts wider than expected Q4 2025 loss yet shares rise 5.28 percent on bullish investor sentiment.ADR - UBND thành phố Hải Phòng
[Form 4] Minerva Neurosciences, Inc. Insider Trading Activity - Stock Titan
Minerva Neurosciences (NERV) officer James O’Connor files Form 3 - Stock Titan
NERV Initiates Coverage On Citizens -- Rating Set to Market Outp - GuruFocus
Minerva stock wins New Outperform at Citizens (NERV:NASDAQ) - Seeking Alpha
Minerva Neurosciences (NASDAQ:NERV) Now Covered by Citizens Jmp - MarketBeat
Citizens initiates Minerva Neurosciences stock at outperform, $14 target By Investing.com - Investing.com South Africa
Citizens initiates Minerva Neurosciences stock at outperform, $14 target - Investing.com
Minerva Neurosciences, Inc (NASDAQ:NERV) Sees Significant Growth in Short Interest - MarketBeat
NRG Fusion Market Competitive Landscape Report 2026 Featuring Zensun (Shanghai) Sci & Tech, Salubris Biotherapeutics, Hummingbird Bioscience, Minerva Neurosciences - Yahoo Finance
Retail Surge: Is Minerva Neurosciences Inc stock technically oversold2026 Breakouts & Breakdowns & Weekly Watchlist of Top Performers - baoquankhu1.vn
Minerva Neurosciences (NASDAQ: NERV) proxy: charter amendments, say‑on‑pay vote - Stock Titan
Minerva Neurosciences (NASDAQ:NERV) Shares Cross Below Fifty Day Moving AverageShould You Sell? - MarketBeat
Minerva Neurosciences Sets 2026 Annual Shareholder Meeting Timeline - The Globe and Mail
Minerva Neurosciences, Inc. Files Form 8-K with SEC – Company Information and Key Details (April 6, 2026) 14 - Minichart
Minerva Neurosciences Inc Azioni (NERV) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.98%
0.12%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):